Obesity drug submitted for approval in Japan, Novo Nordisk reports

Novo Nordisk is now aiming to have its weight loss drug Wegovy approved in Japan. In Wednesday's quarterly report, the pharmaceutical company announces that it submitted the marketing application to the Japanese authorities back in August.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

In August, a marketing authorization application for the obesity drug Wegovy was sent off to the Japanese authorities (PMDA), Novo Nordisk reveals in its quarterly report for the third quarter.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading